ACT Capital Management LLC Takes $2.68 Million Position in Structure Therapeutics Inc. Sponsored ADR $GPCR

ACT Capital Management LLC purchased a new stake in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) during the 4th quarter, HoldingsChannel.com reports. The fund purchased 38,500 shares of the company’s stock, valued at approximately $2,678,000. Structure Therapeutics makes up 2.2% of ACT Capital Management LLC’s investment portfolio, making the stock its 13th largest position.

Several other institutional investors have also recently made changes to their positions in the company. CWM LLC increased its stake in shares of Structure Therapeutics by 35.2% during the fourth quarter. CWM LLC now owns 480 shares of the company’s stock valued at $33,000 after buying an additional 125 shares during the period. HighTower Advisors LLC increased its stake in shares of Structure Therapeutics by 3.6% during the fourth quarter. HighTower Advisors LLC now owns 9,320 shares of the company’s stock valued at $648,000 after buying an additional 320 shares during the period. State of Wyoming increased its stake in shares of Structure Therapeutics by 29.7% during the fourth quarter. State of Wyoming now owns 1,761 shares of the company’s stock valued at $122,000 after buying an additional 403 shares during the period. PNC Financial Services Group Inc. increased its stake in shares of Structure Therapeutics by 9.4% during the third quarter. PNC Financial Services Group Inc. now owns 4,828 shares of the company’s stock valued at $135,000 after buying an additional 413 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of Structure Therapeutics by 4.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,888 shares of the company’s stock valued at $757,000 after buying an additional 444 shares during the period. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Analyst Ratings Changes

GPCR has been the topic of several research reports. William Blair restated an “outperform” rating on shares of Structure Therapeutics in a research note on Monday, March 16th. Canaccord Genuity Group started coverage on Structure Therapeutics in a research note on Monday, April 27th. They issued a “buy” rating and a $101.00 target price on the stock. HC Wainwright cut their target price on Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating on the stock in a research note on Thursday, June 11th. Wall Street Zen lowered Structure Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, Wolfe Research initiated coverage on Structure Therapeutics in a report on Thursday, March 26th. They issued a “peer perform” rating for the company. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $106.75.

Structure Therapeutics Stock Up 4.9%

Shares of NASDAQ GPCR opened at $45.00 on Thursday. The business’s 50 day moving average price is $43.09 and its 200 day moving average price is $57.53. The firm has a market cap of $3.20 billion, a P/E ratio of -51.72 and a beta of -1.35. Structure Therapeutics Inc. Sponsored ADR has a 52 week low of $15.80 and a 52 week high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, May 7th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.04. As a group, research analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -1.64 earnings per share for the current year.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.